[150 Pages Report] Drug Delivery Devices Market size was valued US$ 78.09 billion in 2021 and is estimated to reach US$ 124.83 billion by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).
Drug Delivery Devices Market - Strategic Insights
Drug Delivery Devices Market CAGR
By Type, By Application, By End User, and By Region
Report Insights Covered
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.
Major Companies Covered
Baxter International, Acromed AG, Medtronic, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Novartis AG, 3M, Sanofi, Merck & Co., Inc, Pfizer Inc, Bayer AG, GlaxoSmithKline plc, Novosanis, among others
To Get a Free Sample Click here
Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent through a specific route of administration into the human body and various systems. These devices can be used once or multiple times for medical treatments.
The drug delivery devices market growth is driven by several factors including, the rising prevalence of chronic diseases, growth in the biologics market, technological advancements, and new product launches. Also, due to the outbreak of coronavirus worldwide, there is a sudden increase in the demand for pharmaceutical drugs largely for infectious applications.
Increasing prevalence of chronic diseases and rising government funds are expected to drive the market growth.
Due to this high prevalence of cancer, increasing efforts are being made in R&D for the development of novel drug delivery systems for providing better treatment to patients. The use of innovative technologies in drug deliveries for cancer treatment is driving the market. The increasing need for self-administration of drugs as in the case of diseases such as diabetes has enhanced the size of the needle-free drug delivery devices industry.
The drug delivery device has seen plenty of innovation over the years. The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.
For instance, Cincinnati-based Enable 2019 partnered with Sanofi to develop long-term manufacturing and supply arrangements using multiple molecule development programs provided by the company. Enable Injections is developing a subcutaneous drug delivery platform with the enFuse, which works as an on-body patch. enFuse enables patient-administered subcutaneous delivery of high-volume therapeutics outside of the hospital. The on-body drug delivery platform has a self-contained drug transfer system that is compatible with standard syringes and vial container formats.
To simplify drug delivery for patients and practitioners, drug-delivery devices are becoming more complex. Many of today’s devices include special features designed to ease self-dosing and encourage patient adherence to novel regimens. Wearable devices are further easing use by promoting active lifestyles. And some devices are offering connectivity to support digital health monitoring.
Stringent regulations in pharma and poor quality are expected to hamper the market growth.
The quality and regulatory requirements in each industry are slightly different, and often the biggest challenges emerge when companies aren’t aware that the constituent products of a combination product are also governed slightly differently.
In recent years, there has been numerous product recalls in the injectable drug delivery segment. Recalls can be voluntary or can result after the intervention of regulatory authorities. Usability issues must be identified and addressed during the development process. The presence of visible foreign matter during the testing of retention samples in injectable can cause severe health consequences such as permanent impairment of a body function, damage and/or obstruction of blood vessels, local inflammation, phlebitis, allergic response, and/or embolization in the body and infection. Other reasons due to which injectable face recalls are contamination from inorganic materials such as glass, silicone, and stainless steel, and also due to incomplete filling of vials.
If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with the replacement and fixing of faulty products. These huge losses will affect the revenue and the share of the company in the market, which in turn will impact the overall market. The key challenges are less about the technology itself and more about the integration of two distinct worlds pharma and medical device.
The global drug delivery devices market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, pricing analysis and unmet needs.
COVID-19 Impact Analysis
At the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments are working toward offering efficient medical treatment to the COVID-19 patients, and drug delivery devices are expected to play a vital role in this context. The project is being worked toward developing principles for nasal immunization, developing a biomimetic nanoparticle provided with both immune enhancers and a targeting protein. In addition, COVID-19 has put the market in front of mind, with unparalleled demand for some products like Injectable drug delivery and nebulizer.
Considering that aerosol therapy generates fugitive emissions that are not inhaled by the patient and are released from the device during expiration, several international professional bodies have provided recommendations for drug delivery via inhalers and in particular, nebulizers. Because of the dramatic drop in elective medical procedures, many of which are being postponed or cancelled so that hospitals can focus resources on treating COVID-19 patients results in a drop in the use of other products. The pandemic is encouraging new avenues for drug delivery device development and marketing. COVID-19 has the potential to prompt a sea change in the drug delivery device industry. This may involve a shift towards entirely new drug delivery device manufacturing systems, forcing many companies to adopt new technology.
Injectable drug delivery segment is expected to hold the largest market share in global drug delivery devices market
According to the research report the global market is classified into route of administration, application, and end user.
Based on the route of administration, the market is subdivided into oral drug delivery, injectable drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, implantable drug delivery, and passive implantable drug delivery. based on application it is further divided into infectious diseases, cancer, autoimmune diseases, central nervous system disorders, respiratory diseases, and diabetes. based on end-user segment into hospitals, ambulatory surgery centers, home care settings, diagnostic centers, and others.
The injectable drug delivery segment is expected to grow with the increasing technological advancements and demand for biologics. The injectable drug delivery devices are projected to grow fastly due to the growing burden of chronic diseases, benefits, and convenience, which will lead to increased demand for self-injectors and growth in the biologics market, which will lead to increased demand for injectors. With the introduction of self-injection devices such as auto-injectors, pen-injectors, and needle-free injectors, the use of injectable drug delivery (IDD) has become relatively simple, allowing patients to administer drugs at home without the assistance of a medical professional.
Self-Injection devices are injections or wearable devices that a patient can use at home to administer medication to themselves. Self-injection devices give patients with chronic diseases control over their treatment schedule and treatment setting, allowing them more independence and freedom in their social, domestic, and professional lives.
Many companies are manufacturing self-injection devices. For instance, on April 13th, 2021, the FDA approved Roche company's supplemental Biologics License Application for Xolair(omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the first and only FDA-approved biologic for treating moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU), and nasal polyps.
An injector pen is a device used to administer medication through the skin. Injector pens are intended to make injectable medication more accessible and convenient to use. Pen injectors were created for patients who require a continuous long-term dosage of hormones and medications to manage conditions such as diabetes. They are available in both disposable and reusable forms. The increasing advancements are expected to fuel the market growth of this segment.
An autoinjector is a device designed to deliver a specific drug dose. The majority of autoinjectors are single-use, disposable spring-loaded syringes. Autoinjectors are designed to be simple and intended for self-administration by patients or administration by untrained personnel. The injection site varies depending on the drug, but it is usually in the thigh or buttocks.
Wearable injectors are expected to show at highest growth rate during the forecast period. These wearable injectors are delivery systems that attach to the body and allow for administering larger volumes (more than 2 mL) of drug subcutaneously over an extended period. Wearable injectors are used for high-volume medications, pharmaceutical formulations with high viscosities (e.g., monoclonal antibodies), and regimens requiring timed medication injection over a long period. On-body injectors are most useful when wearable injectors are used as an alternative to admitting the patient to a medical facility for clinical support of an injection.
North America region holds the largest market share in the global drug delivery devices market
As per the research study, the global market is divided into majorly five regions such as North America, South America, Europe, the Middle East, Africa, Asia Pacific, and the Rest of the world.
The drug delivery devices market in North America is estimated to grow at a highest CAGR during the forecast period. The United States owns the largest share of the market in the North American region. Heart disease is a leading cause of death that creates an enormous burden on people, communities, and healthcare providers and systems. The rising prevalence of cancer in the region is also driving the growth of the market in the region. According to the National Cancer Institute, 2019, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices.
In addition, growing product approval in countries such as the U.S. is also expected to contribute to market growth. In March 2019, Aptar Pharma received U.S. FDA approval for nasal drug delivery devices. Hence, the increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.
Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the Europe. Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the region.
Factors such as the increasing prevalence of chronic diseases such as cancer and diabetes, increased demand for self-injection devices particularly pen injectors, technological advancements, patient compliance, and the presence of key market players in Germany are driving the growth of this market in the country. Germany has the presence of all the major pharmaceuticals and biotechnology companies. The companies are constantly taking initiatives to introduce new products in order to grow their presence in the market.
The Asia Pacific is expected to experience the fastest growth rate during the forecast period owing to high economic growth in the region. Moreover, a large patient pool in countries like Japan, China, and India is also leading to the adoption of drug delivery devices by various end-users. The growth in the region is mainly attributed to higher usage of drug delivery systems in healthcare facilities, availability of reimbursement for the majority of the population, increasing prevalence of chronic diseases (diabetes and cancer), growing geriatric population, increased understanding of drug metabolism and increased preference for individual and customized therapy, especially for cancer.
In Japan, different types of drug delivery devices are coming into use for delivering specific types of drugs. In December 2019, YpsoMate autoinjector entered the Japanese market for accurate delivery of Teribone drug. The major factors attributing to the growth of the Chinese drug delivery devices market are the growing burden of chronic diseases benefits, and convenience, leading to increased demand for self-injectors leading to increased demand for drug delivery devices.
The drug delivery devices market is highly competitive and consists of several major players and the emergence of new players in the market. Some of the key players which are contributing to the growth of the market are Baxter International, Acromed AG, Medtronic, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Novartis AG, 3M, Sanofi, Merck & Co., Inc, Pfizer Inc, Bayer AG, GlaxoSmithKline plc, Novosanis, among others.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the global market for drug delivery devices. For instance,
Global Drug Delivery Devices Market – Key Companies to Watch
Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.
NEXJECT Prefilled Syringe: Nexject is a prefilled all in one syringe that contains multiple levels of technology such as temper-resistant and temper-evident. It is developed for efficient and easy delivery of medicines.
Key Developments: In Jan 2022, Pfizer announced its development and option agreement with Acuitas Therapeutics, company that develops lipid nanoparticle delivery system and m-RNA based therapeutics.
The global drug delivery devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
What is the Projected CAGR value of the Drug Delivery Devices Market?
Drug Delivery Devices Market is expected to grow at a CAGR of 7.60% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Drug Delivery Devices Market during 2022-2029
Which is the fastest growing region in the Drug Delivery Devices Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
Get your free sample proposal with a single click!